Stay up-to-date with news about NeuroPro’s clinical development progress

Key milestones

March 2024: NeuroPro secures $23 million to advance development of NPT 2042 to treat epilepsy.

December 2023: NeuroPro presents Phase 2 study design at the American Epilepsy Society (AES) meeting.

Board Meeting on December 1, 2023
NeuroPro President, Daryl Hochman, PhD presented an overview of the novel mechanism of action of NPT 2042, the safety data, and the planned Phase 2 study design at The Epilepsy Study Consortium (TESC)

March 2023: NeuroPro completes NPT 2042 Phase 1 study.

February 2023: NeuroPro secures $5 million in equity funding to prepare for the Phase 2 program.

October 2022: NeuroPro initiates Phase 1 study.

August 2022: NeuroPro files an IND with the FDA to initiate a Phase 1 study.

2019: NeuroPro secures $10 million for preclinical development and a Phase 1 study.